Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Florbetapir F18 AV45 F18

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Amyloid
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Obtain diagnostic data using a PET amyloid tracer (Florbetapir F18 AV45 F18), an in-vivo marker of one of the neuropathological lesions that define AD, of in order to enhance diagnostic accuracy AD in these patients. This approach will validate the hypothesis as to whether the assessment of subhippocampal dysfunction can contribute to the early diagnosis of AD.

Target Population/ Population Being Studied

Patients with early AD and healthy controls

Length of Current Trial
24 months
Number of Trial Participants

80

Estimated Trial Completion
November 2017 Clinical trials says this is active but the end date has passed
What is Required from Patients

injection of radioactive tracers, mild discomfort, in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes

Sponsor

Assistance Publique Hopitaux De Marseille

“Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT01746706?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=12&rank=103